APA (7th ed.) Citation

Grosu, A., Weber, W. A., Graf, E., Mix, M., Nestle, U., Schimek-Jasch, T., . . . Sperk, E. (2026). O-(2-(18F)fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): A multicentre, open-label, randomised trial. The lancet. Oncology, 27(2), . https://doi.org/10.1016/S1470-2045(25)00642-4

Chicago Style (17th ed.) Citation

Grosu, Anca-Ligia, et al. "O-(2-(18F)fluoroethyl)-L-tyrosine-PET-guided Versus Contrast-enhanced T1-weighted MRI-guided Re-irradiation in Patients with Recurrent Glioblastoma (GLIAA/NOA-10 ARO2013-01): A Multicentre, Open-label, Randomised Trial." The Lancet. Oncology 27, no. 2 (2026). https://doi.org/10.1016/S1470-2045(25)00642-4.

MLA (9th ed.) Citation

Grosu, Anca-Ligia, et al. "O-(2-(18F)fluoroethyl)-L-tyrosine-PET-guided Versus Contrast-enhanced T1-weighted MRI-guided Re-irradiation in Patients with Recurrent Glioblastoma (GLIAA/NOA-10 ARO2013-01): A Multicentre, Open-label, Randomised Trial." The Lancet. Oncology, vol. 27, no. 2, 2026, https://doi.org/10.1016/S1470-2045(25)00642-4.